Mission Statement, Vision, & Core Values of Altimmune, Inc. (ALT)

Ever wondered what drives a biopharmaceutical company like Altimmune? Understanding their mission, vision, and core values provides insight into their goals and how they operate. But how do these statements translate into real-world performance, especially when considering the financials? In 2024, Altimmune reported research and development expenses of $82.2 million and general and administrative expenses of $21.0 million, with cash, cash equivalents, and short-term investments totaling $131.9 million as of December 31, 2024.

What exactly does Altimmune aim to achieve, and what principles guide their journey? How do these values align with their strategic focus on developing innovative therapies, particularly for conditions like obesity and MASH (metabolic dysfunction-associated steatohepatitis)? Read on to explore the mission, vision, and core values that shape Altimmune's path in the biopharmaceutical industry.

Altimmune, Inc. (ALT) An Overview of

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for the treatment of obesity and liver diseases. As of April 2025, the company's primary focus remains on advancing its pipeline of innovative therapies to address significant unmet medical needs.

Altimmune's pipeline includes:

• Pemvidutide: A GLP-1/glucagon dual receptor agonist under development for obesity and non-alcoholic steatohepatitis (NASH).
• HepTcell: An immunotherapeutic designed to achieve a functional cure for chronic hepatitis B.
• AdCOVID: A single-dose intranasal vaccine candidate for COVID-19 (though development status may vary as of April 2025).

The company operates in the competitive biopharmaceutical industry, where innovation and clinical trial success are critical for growth and market capitalization.

As a clinical-stage company, Altimmune's financial performance is closely tied to its research and development activities, clinical trial outcomes, and ability to secure partnerships and funding. For the fiscal year 2024, Altimmune reported a net loss of $121.2 million, or $2.34 per share, compared to a net loss of $93.3 million, or $2.47 per share, for the year 2023. Research and development expenses increased to $97.1 million in 2024 from $73.9 million in 2023, primarily due to increased clinical trial expenses associated with the pemvidutide program. General and administrative expenses were $26.4 million in 2024, compared to $21.3 million in 2023. As of December 31, 2024, Altimmune had cash, cash equivalents, and short-term investments totaling $203.7 million. These resources are expected to fund operations into the second half of 2026, based on current projections.

Altimmune is striving to be a leader in developing treatments for obesity and liver diseases. Its focus on innovative peptide-based therapeutics and strategic approach to clinical development underscores its ambition. To delve deeper into Altimmune's journey, explore: Altimmune, Inc. (ALT): History, Ownership, Mission, How It Works & Makes Money

Altimmune, Inc. (ALT) Mission Statement

Altimmune, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for obesity and liver diseases. As of 2024, Altimmune's mission is focused on addressing significant unmet needs in these therapeutic areas through innovative peptide-based therapeutics. The company aims to improve patient outcomes by developing treatments that offer better efficacy, safety, and convenience compared to existing options.

The core components of Altimmune's mission statement can be broken down into three key areas:

• Focus on Obesity and Liver Diseases: Altimmune concentrates its research and development efforts on addressing the growing global health challenges posed by obesity and liver diseases.
• Innovative Peptide-Based Therapeutics: The company is committed to developing novel therapies using its expertise in peptide technology.
• Improving Patient Outcomes: Altimmune's ultimate goal is to enhance the lives of patients by providing them with more effective, safer, and convenient treatment options.

Focus on Obesity and Liver Diseases

Altimmune strategically focuses on obesity and liver diseases due to the increasing prevalence and significant impact of these conditions on global health. Obesity, often linked to various comorbidities such as type 2 diabetes, cardiovascular disease, and non-alcoholic steatohepatitis (NASH), represents a major public health concern. Similarly, liver diseases, including NASH and chronic hepatitis B, affect millions worldwide and can lead to severe complications such as cirrhosis and liver cancer.

As of 2024, statistics highlight the urgency of addressing these conditions:

• Obesity: The World Health Organization (WHO) estimates that over 650 million adults worldwide are obese.
• NASH: NASH affects approximately 3-5% of adults in the United States, and its prevalence is expected to rise in the coming years.

By concentrating on these therapeutic areas, Altimmune aims to leverage its scientific expertise to develop targeted therapies that can make a meaningful difference in patient care.

Innovative Peptide-Based Therapeutics

Altimmune distinguishes itself through its commitment to developing innovative peptide-based therapeutics. Peptides, short chains of amino acids, offer several advantages as therapeutic agents, including high specificity, reduced toxicity, and ease of manufacturing. Altimmune utilizes its proprietary peptide technology platforms to design and develop novel drug candidates that target specific pathways involved in obesity and liver diseases.

The company's lead product candidates, such as pemvidutide, a GLP-1 receptor agonist, exemplify its innovative approach to drug development. Pemvidutide has shown promising results in clinical trials, demonstrating significant weight loss and improvements in metabolic parameters in obese patients. Altimmune continues to invest in research and development to expand its pipeline of peptide-based therapeutics and explore new applications for its technology.

Improving Patient Outcomes

Altimmune's overarching mission is to improve patient outcomes by providing them with more effective, safer, and convenient treatment options. The company recognizes that existing therapies for obesity and liver diseases often have limitations, such as modest efficacy, significant side effects, or inconvenient routes of administration. Altimmune strives to overcome these challenges by developing novel therapies that offer superior clinical benefits and enhance the overall patient experience.

Altimmune's commitment to improving patient outcomes is reflected in its clinical development strategy, which emphasizes rigorous study design, patient-centric endpoints, and close collaboration with regulatory agencies. The company is dedicated to conducting clinical trials that generate high-quality data and provide clear evidence of the safety and efficacy of its drug candidates. By prioritizing patient needs and scientific excellence, Altimmune aims to make a lasting impact on the lives of individuals affected by obesity and liver diseases.

To gain further insights into Altimmune, Inc., explore this resource: Altimmune, Inc. (ALT): History, Ownership, Mission, How It Works & Makes Money

Altimmune, Inc. (ALT) Vision Statement of

Altimmune, Inc. is a clinical-stage biopharmaceutical company dedicated to developing treatments for obesity and liver diseases. Understanding Altimmune's strategic direction requires a close examination of its mission, vision, and core values. As of April 2025, these elements guide the company's operations and long-term goals.

Mission Statement

Altimmune's mission is focused on developing innovative therapies to address significant unmet needs in obesity and liver diseases. This involves:

• Advancing a pipeline of differentiated product candidates.
• Leveraging proprietary technology platforms for peptide-based therapeutics.
• Conducting rigorous clinical trials to demonstrate safety and efficacy.
• Seeking regulatory approvals to bring new treatments to market.

This mission is reflected in their ongoing clinical programs. For example, Altimmune is currently focusing on advancing pemvidutide, a GLP-1 receptor agonist, through Phase 2 clinical trials for obesity and NASH (nonalcoholic steatohepatitis). Pemvidutide has shown promising results in early trials, demonstrating significant weight loss and improvements in liver health markers.

Vision Statement

While a specific, publicly declared vision statement for Altimmune is not readily available, we can infer their vision from their strategic goals and public statements. Altimmune envisions becoming a leader in the treatment of obesity and liver diseases by:

• Developing best-in-class therapeutics that offer superior efficacy and safety profiles.
• Transforming the treatment landscape for patients with obesity and liver diseases.
• Creating significant value for shareholders through successful product development and commercialization.

This vision aligns with the broader trends in the biopharmaceutical industry, where there is increasing demand for innovative treatments for metabolic and liver diseases. The obesity market, for instance, is projected to reach $44.6 billion by 2027, driven by the rising prevalence of obesity and the growing awareness of its associated health risks.

Core Values

Altimmune's core values are not explicitly detailed in their public statements, but can be inferred from their actions and priorities. These likely include:

• Innovation: A commitment to developing novel therapies using cutting-edge science and technology.
• Integrity: Adherence to the highest ethical standards in research, development, and business practices.
• Patient Focus: A dedication to improving the lives of patients with obesity and liver diseases.
• Excellence: A pursuit of excellence in all aspects of their operations, from research and development to manufacturing and commercialization.

These values are evident in their approach to clinical development, where they prioritize rigorous scientific methodology and patient safety. For example, Altimmune's clinical trials are designed to meet the highest standards of regulatory agencies such as the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency).

To gain more insights into Altimmune's financial stability, see Breaking Down Altimmune, Inc. (ALT) Financial Health: Key Insights for Investors.

Altimmune, Inc. (ALT) Core Values of

While specific details on Altimmune's core values are not explicitly available, we can infer their commitment through their actions, programs, and initiatives. Here's an analysis based on available information:

Focus on Innovation

Innovation appears to be a core value for Altimmune, driven by their dedication to developing novel therapeutic solutions. This is evident in their focus on areas like:

• Obesity and Metabolic Diseases: Altimmune is developing treatments for obesity, a significant and growing global health challenge. Their investigational drug pemvidutide is a GLP-1 receptor agonist, targeting weight loss and improvements in metabolic function. In a 48-week study, pemvidutide demonstrated a mean weight loss of 15.6% in participants without diabetes.
• Liver Diseases: Altimmune is also focusing on developing treatments for liver diseases, including NASH (nonalcoholic steatohepatitis). Their pipeline includes treatments aimed at addressing the underlying causes of these conditions.
• Immune Modulating Therapies: Altimmune is working on therapies that modulate the immune system to fight diseases, as evidenced by their research and development efforts in this area.

Altimmune's pipeline includes several innovative product candidates:

• Pemvidutide: A GLP-1 receptor agonist for obesity and NASH.
• HepTcell: An immunotherapeutic for chronic Hepatitis B.
• AdCOVID: A single-dose intranasal vaccine candidate for COVID-19 (though development was discontinued).

Commitment to Scientific Rigor and Clinical Excellence

Altimmune places a high value on scientific rigor, which is crucial in the biotechnology industry. This is reflected in their approach to clinical trials and data analysis. For example:

• Clinical Trial Design: Altimmune conducts rigorous clinical trials to evaluate the safety and efficacy of their drug candidates. These trials are designed to meet regulatory standards and provide meaningful data.
• Data Transparency: Altimmune is committed to transparency in reporting clinical trial results. This includes publishing data in peer-reviewed journals and presenting findings at scientific conferences.

Patient-Centric Approach

Altimmune appears to prioritize the well-being of patients, which is demonstrated through their development of treatments designed to address unmet medical needs. Examples include:

• Addressing Obesity: Altimmune recognizes the significant health challenges associated with obesity and is developing treatments to help patients achieve and maintain weight loss.
• Treating Liver Diseases: Altimmune is focused on developing therapies for liver diseases like NASH, which can lead to serious complications if left untreated.
• Improving Vaccination: Altimmune aimed to develop an easy-to-administer nasal vaccine for COVID-19, reflecting a patient-centric approach to vaccination.

For more insights into Altimmune's history and mission, explore: Altimmune, Inc. (ALT): History, Ownership, Mission, How It Works & Makes Money